INO vs USB · rev $65.3K vs P/E 12, rev $28.66B
Inovio Pharmaceuticals Inc (INO) versus U.S. Bancorp (USB) — a side-by-side from cached financials, not a winner call.
Inovio Pharmaceuticals Inc (INO) is a biotechnology company listed on US.
U.S. Bancorp (USB) is a banks - regional company listed on US.
Latest reported INO revenue for 2025-12-31 was $65.3K. Net income was -$84.9M. Revenue was down 70.0% from 2024-12-31 to 2025-12-31. INO currently screens at market cap $88.0M.
Latest reported USB revenue for 2025-12-31 was $28.66B. Net income was $7.57B. Revenue was up 4.4% from 2024-12-31 to 2025-12-31. USB currently screens at market cap $74.68B and trailing P/E 11.9.
INO currently screens at market cap $88.0M. USB currently screens at market cap $74.68B and trailing P/E 11.9.
Not investment advice. Open the INO and USB stock pages for the full models.
Not investment advice.